Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib
Background: Despite the approval of mTOR inhibitor everolimus and CDK4/6 inhibitors in the management of hormone-receptor-positive HER2 non-amplified metastatic breast cancer (HR+ HER2-MBC), the optimal sequence of therapy is unclear. There are no clinical data on efficacy of everolimus in HR+ HER2-...
Main Authors: | Ajay Dhakal, Roby Antony Thomas, Ellis G Levine, Adam Brufsky, Kazuaki Takabe, Matthew G Hanna, Kristopher Attwood, Austin Miller, Thaer Khoury, Amy P Early, Saif Soniwala, Tracy O’Connor, Mateusz Opyrchal |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2020-07-01
|
Series: | Breast Cancer: Basic and Clinical Research |
Online Access: | https://doi.org/10.1177/1178223420944864 |
Similar Items
-
320 Phase IIa study of alpha-DC1 vaccine against HER2/HER3, chemokine modulation regimen and pembrolizumab in patients with asymptomatic brain metastasis from triple negative or HER2+ breast cancer
by: Pawel Kalinski, et al.
Published: (2020-11-01) -
Cytotoxic T-lymphocyte infiltration and chemokine predict long-term patient survival independently of tumor mutational burden in triple-negative breast cancer
by: Eriko Katsuta, et al.
Published: (2021-04-01) -
Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01) -
Palbociclib in breast cancer neoadjuvant setting
by: Sílvia Alexandra Cabral Duarte, et al.
Published: (2021-08-01) -
Determination of palbociclib by high performance liquid chromatography
by: Xiaodong SHI, et al.
Published: (2017-08-01)